Immix Biopharma Announces Other Serious Diseases Strategy

Core Insights - Immix Biopharma is focused on advancing its lead candidate, NXC-201, a BCMA-targeted CAR-T cell therapy, for relapsed/refractory AL Amyloidosis, with plans for a Biologics License Application (BLA) submission [1][2][3] - The company is also exploring partnerships to license out its Other Serious Disease (OSD) programs, leveraging promising clinical results from NXC-201 [2][3] Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases [3] - NXC-201 is currently being evaluated in a U.S. multi-center study (NEXICART-2) for relapsed/refractory AL Amyloidosis, with interim results presented at ASCO 2025 [3] - The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the FDA and EMA [3]